We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current ACST market cap is 5.45M. The company's latest EPS is USD -1.3675 and P/E is -2.46.
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 196k | 0 | 0 | 0 |
| Operating Income | -24.44M | -16.01M | -15.34M | -52.16M | -12.85M |
| Net Income | -25.51M | -19.68M | -9.82M | -42.43M | -12.85M |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 22.85M | 62.46M | 128.62M | 79.12M | 73.3M |
| Total Liabilities | 9.86M | 6.8M | 20.35M | 11.17M | 11.56M |
| Total Equity | 12.99M | 55.66M | 108.27M | 67.96M | 61.74M |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -22.94M | -14.32M | -17.23M | -15.91M | -12.33M |
| Investing | 8.14M | -9.86M | -3.52M | 13.15M | 104k |
| Financing | 13.18M | 59.49M | N/A | 304k | 7.36M |
| Market Cap | 5.45M |
| Price to Earnings Ratio | -2.46 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 1.38 |
| Price to Book Ratio | 0.51 |
| Dividend Yield | - |
| Shares Outstanding | 9.4M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 0.58 |
| 52 Week Low | 0.58 |
| Spread (Intraday) | 0.4 (40.82%) |
| Company Name | Acasti Pharma Inc |
| Address |
103 carnegie center jersey city, new jersey 08540 |
| Website | https://www.acastipharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
